LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
21 funds hold it · Insiders net selling
Net selling: insiders sold $1.3M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $18K to $95K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 3, 2026
Period ending
Oct 4, 2026
Earnings per share
$1.29 expected
Estimates as of Nov 9, 2026
EPS expected
$1.58 to $1.62
Revenue expected
14 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Oct 4, 2026Reported Nov 3, 2026 | $1.38est. $1.29 | +6.98%beat | $728.9MSEC filing | +4.3%from $698.9M |
| Jul 5, 2026Reported Jul 27, 2026 | $1.41est. $1.23 | +14.63%beat | $729.7MSEC filing | +1.3%from $720.3M |
| Apr 5, 2026Reported May 5, 2026 | $1.06est. $1.01 | +4.95%beat | $711.1MSEC filing | +7.0%from $664.8M |
| Dec 31, 2025Reported Feb 2, 2026 | $1.70est. $1.58 | +7.59%beat | $772.1MAlpha Vantage | +5.9%from $729.4M |
| Sep 28, 2025Reported Oct 27, 2025 | $1.18est. $1.14 | +3.51%beat | $698.9MSEC filing | +2.2%from $684.0M |
| Jun 29, 2025Reported Jul 28, 2025 | $1.18est. $1.14 | +3.51%beat | $720.3MSEC filing | +4.1%from $691.7M |
| Mar 30, 2025Reported Apr 28, 2025 | $1.01est. $0.95 | +6.32%beat | $664.8MSEC filing | +2.3%from $649.9M |
| Dec 31, 2024Reported Jan 31, 2025 | $1.42est. $1.38 | +2.90%beat | $729.4MAlpha Vantage | +4.8%from $695.9M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $772.1M | $711.1M | $729.7M | $728.9M |
| Cost of what it sold | $433.9M | $323.5M | $312.8M | $310.3M |
| Gross profit | $338.1M | $387.7M | $416.9M | $418.6M |
| What it spent | ||||
| Research and development | $58.2M | $57.9M | $49.0M | $48.1M |
| Sales and admin | $251.7M | $253.9M | $280.0M | $275.3M |
| Other operating costs | -$83.5M | — | — | — |
| Total operating expenses | $226.4M | $311.8M | $327.6M | $323.4M |
| What was left | ||||
| Operating profit | $111.7M | $75.9M | $89.3M | $95.1M |
| Interest on debt | $23.5M | $24.7M | $23.0M | $20.8M |
| Profit before tax | $91.6M | $50.0M | $63.5M | $77.7M |
| Tax | -$6.8M | $9.1M | $10.1M | $15.1M |
| Net profit | $98.4M | $40.7M | $51.8M | $62.3M |
| EBITDA | $218.2M | $179.8M | $188.6M | $201.4M |
This stock is in a strong uptrend.
Trend
Strong uptrend
80 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Life Sciences revenue rises 11% at Revvity (RVTY), but Diagnostics moves the other way.
Leans bullishNov 10Corvus Pharmaceuticals advances with soquelitinib, funded through 2028, eyeing key clinical results in 2027.
Leans bullishNov 10In Vitro Toxicology Testing - Global Strategic Business Report: Capitalize on the $14B-to-$27.4B Surge as Thermo Fisher Scientific, Merck, Eurofins and Bio-Rad Disrupt Testing by 2032
Leans bullishNov 10A 36% narrower Q3 loss at Quanterix (QTRX) comes alongside a revenue decline.
NeutralNov 9RVTY: Recovery Looks Firmer, But Better Growth And Margins Still Look Priced In
NeutralNov 7Revvity Inc. stock outperforms competitors on strong trading day
BullishNov 6ETFs Are Net Sellers of Revvity (RVTY) on Nov. 4
Leans bearishNov 6Revvity, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Leans bullishNov 635 macro signals shaping RVTY right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
